News
Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at risk pre-term infants
7 July 2022
Following recent observations of a sustained rise in rates of infections of Respiratory Syncytial Virus (RSV), it has been recommended that the palivizumab passive immunisation programme recommences.